BioNTech acquires T cell therapy-focused Neon for $67m
BioNTech has acquired Neon Therapeutics in an all stock transaction valued at $2.18 per share or approximately $67m. According to the terms of the deal, Neon will be merged with ENDOR Lights, a wholly owned subsidiary of BioNTech.
Dermavant licences Tapinarof commercial rights in Japan
Dermavant Sciences, a subsidiary of Roivant Sciences, has signed an exclusive agreement to licence the development and commercial rights of tapinarof in Japan.
Galapagos expands fibrosis research collaboration with Fibrocor
Galapagos has expanded its research collaboration with Candian firm Fibrocor Therapeutics, which develops tissue-specific therapeutics for fibrotic diseases.
Bioequivalence Studies Conduct CRO
For more than two decades, CEPHA has built its reputation for conducting high-quality, cost-effective clinical research services. The company takes pride in maintaining high-quality standards and providing robust, reliable, and time-effective results in contract research.
Takeda partners Charles River to develop preclinical candidates
Takeda Pharmaceutical Company has teamed up with Charles River to deliver preclinical candidates across its four core therapeutic areas.
MorphoSys and Incyte sign $900m deal for B-cell malignancies drug
Germany-based MorphoSys has announced it has signed a collaboration and license agreement with the US company Incyte to continue the global development and commercialisation of the former’s tafasitamab (MOR208) for B-cell malignancies.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.